Telix Pharmaceuticals (NASDAQ:TLX) CEO Christian Behrenbruch Acquires 33,435 Shares

Telix Pharmaceuticals Limited (NASDAQ:TLX) CEO Christian Behrenbruch acquired 33,435 shares of the stock in a transaction on Wednesday, April 29th. The stock was purchased at an average cost of $14.87 per share, with a total value of $497,178.45. Following the transaction, the chief executive officer directly owned 20,742,935 shares of the company’s stock, valued at $308,447,443.45. This represents a 0.16% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Christian Behrenbruch also recently made the following trade(s):

• On Tuesday, April 28th, Christian Behrenbruch acquired 34,500 shares of Telix Pharmaceuticals stock. The stock was purchased at an average cost of $14.48 per share, with a total value of $499,560.00.

Telix Pharmaceuticals Price Performance

NASDAQ:TLX traded up $0.07 during trading hours on Wednesday, hitting $11.11. The stock had a trading volume of 87,368 shares, compared to its average volume of 208,018. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Telix Pharmaceuticals Limited has a 1-year low of $6.28 and a 1-year high of $18.49. The business has a 50 day simple moving average of $9.10 and a two-hundred day simple moving average of $8.77.

Telix Pharmaceuticals (NASDAQ:TLX) last issued its quarterly earnings data on Friday, February 20th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.06). The business had revenue of $206.72 million for the quarter, compared to the consensus estimate of $421.50 million. Analysts expect that Telix Pharmaceuticals Limited will post 0.09 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TLX. Rhumbline Advisers grew its stake in Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares during the last quarter. XTX Topco Ltd bought a new position in Telix Pharmaceuticals in the 4th quarter worth about $89,000. IHT Wealth Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at approximately $213,000. OLD Mission Capital LLC bought a new stake in shares of Telix Pharmaceuticals during the fourth quarter valued at approximately $111,000. Finally, Private Advisor Group LLC increased its position in Telix Pharmaceuticals by 67.3% in the 3rd quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock valued at $403,000 after acquiring an additional 16,945 shares during the period.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Citigroup raised their price target on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Wall Street Zen raised shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, January 19th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.13.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.